Biosimilar Market in Europe 2024-2032: Industry Growth, Share, Size, Key Players Analysis and Forecast
IMARC Group, a leading market research company, has recently releases report titled “Biosimilar Market in Europe Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Country 2024-2032” . The study provides a detailed analysis of the industry, including the Europe biosimilar market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market. How Big is the Biosimilar Market in Europe? The biosimilar market in Europe size reached US$ 11,849.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 53,222.9 Million by 2032, exhibiting a growth rate (CAGR) of 17.6% during 2024-2032. Request for a PDF samp...